Dean Ruether

1.0k total citations · 1 hit paper
39 papers, 710 citations indexed

About

Dean Ruether is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Dean Ruether has authored 39 papers receiving a total of 710 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pulmonary and Respiratory Medicine, 13 papers in Oncology and 8 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Dean Ruether's work include Prostate Cancer Treatment and Research (11 papers), Prostate Cancer Diagnosis and Treatment (6 papers) and Radiopharmaceutical Chemistry and Applications (5 papers). Dean Ruether is often cited by papers focused on Prostate Cancer Treatment and Research (11 papers), Prostate Cancer Diagnosis and Treatment (6 papers) and Radiopharmaceutical Chemistry and Applications (5 papers). Dean Ruether collaborates with scholars based in Canada, United States and India. Dean Ruether's co-authors include Srikala S. Sridhar, Peter Albers, Jonathan E. Rosenberg, David C. Smith, Daniel P. Petrylak, Xiaoyu Jia, Brian S. Henick, Glenn Heller, Kim Chi and Amal Melhem‐Bertrandt and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Urology and Annals of Oncology.

In The Last Decade

Dean Ruether

36 papers receiving 695 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4–Positive Solid Tumors, Including Metastatic Urothelial Carcinoma

2020 223 citations Jonathan E. Rosenberg, Srikala S. Sridhar et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Dean Ruether Canada	12	263	242	213	106	103	39	710
Soon‐Beom Kang South Korea	24	312 1.2×	152 0.6×	288 1.4×	239 2.3×	176 1.7×	62	1.5k
Fang Cheng China	18	182 0.7×	162 0.7×	250 1.2×	152 1.4×	41 0.4×	59	789
Anne-Sophie Veillard Australia	15	261 1.0×	235 1.0×	118 0.6×	118 1.1×	50 0.5×	29	754
Tian Tian China	19	279 1.1×	242 1.0×	86 0.4×	229 2.2×	63 0.6×	70	892
Kenneth Wong United States	17	112 0.4×	177 0.7×	121 0.6×	81 0.8×	113 1.1×	53	829
Hye Sook Han South Korea	19	352 1.3×	258 1.1×	141 0.7×	229 2.2×	64 0.6×	72	789
Xiaoqing Xu China	17	209 0.8×	223 0.9×	147 0.7×	177 1.7×	66 0.6×	48	769
Kelsey C. Stoltzfus United States	12	360 1.4×	224 0.9×	136 0.6×	86 0.8×	95 0.9×	17	745
Magdalena Cwikiel Sweden	16	229 0.9×	224 0.9×	309 1.5×	123 1.2×	82 0.8×	23	790
Che‐Kai Tsao United States	15	260 1.0×	356 1.5×	253 1.2×	158 1.5×	58 0.6×	80	769

Countries citing papers authored by Dean Ruether

Since Specialization

Citations

This map shows the geographic impact of Dean Ruether's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dean Ruether with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dean Ruether more than expected).

Fields of papers citing papers by Dean Ruether

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dean Ruether. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dean Ruether. The network helps show where Dean Ruether may publish in the future.

Co-authorship network of co-authors of Dean Ruether

This figure shows the co-authorship network connecting the top 25 collaborators of Dean Ruether. A scholar is included among the top collaborators of Dean Ruether based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dean Ruether. Dean Ruether is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cook, Sarah, Kosuke Takemura, Daniel Yick Chin Heng, et al.. (2024). Real-world Clinical Outcomes and Prognostic Factors in Neuroendocrine Prostate Cancer. Clinical Genitourinary Cancer. 23(1). 102274–102274. 1 indexed citations

Ruether, Dean, et al.. (2024). Resolution of PTHrP-Mediated Hypercalcemia Following Treatment with Dual BRAF/MEK Inhibition for BRAFV600E-Positive Metastatic Ameloblastoma. Calcified Tissue International. 114(4). 444–449. 2 indexed citations

Watson, Linda, et al.. (2024). Creating and implementing a medical consultation recording app: Improving health information recall and shared decision-making with My Care Conversations. Health Informatics Journal. 30(4). 1217785680–1217785680.

Cheung, Winson Y., Dean Ruether, Aynharan Sinnarajah, et al.. (2023). Safe Prescribing Practices: Clinicians' Views on Prescribing Opioids to Patients With Early-Stage Cancer. JCO Oncology Practice. 19(7). 456–464. 2 indexed citations

Lee‐Ying, Richard M., Dylan E. O’Sullivan, Nimira Alimohamed, et al.. (2022). Stage migration of testicular germ cell tumours in Alberta, Canada, during the COVID-19 pandemic: a retrospective cohort study. CMAJ Open. 10(3). E633–E642. 2 indexed citations

Boucher, Andrée, Shereen Ezzat, Sébastien J. Hotte, et al.. (2021). Canadian consensus statement on the management of radioactive iodine–resistant differentiated thyroid cancer. Oral Oncology. 121. 105477–105477. 12 indexed citations

Kolinsky, Michael, Bryan Donnelly, Adrian Fairey, et al.. (2020). Cohort profile: the Alberta Prostate Cancer Research Initiative (APCaRI) Registry and Biorepository facilitates technology translation to the clinic through the use of linked, longitudinal clinical and patient-reported data and biospecimens from men in Alberta, Canada. BMJ Open. 10(10). e037222–e037222. 9 indexed citations

Rosenberg, Jonathan E., Srikala S. Sridhar, Jingsong Zhang, et al.. (2020). EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4–Positive Solid Tumors, Including Metastatic Urothelial Carcinoma. Journal of Clinical Oncology. 38(10). 1041–1049. 223 indexed citations breakdown →

Cuthbert, Colleen, Kathryn King‐Shier, Dianne M. Tapp, Dean Ruether, & S. Nicole Culos‐Reed. (2017). Exploring Gender Differences in Self-Reported Physical Activity and Health Among Older Caregivers. Oncology nursing forum. 44(4). 435–445. 8 indexed citations

10.

Park, Joanne L., K. Brooke Russell, Kathleen Reynolds, et al.. (2017). Unmet Needs of Adult Survivors of Childhood Cancers: Associations with Developmental Stage at Diagnosis, Cognitive Impairment, and Time from Diagnosis. Journal of Adolescent and Young Adult Oncology. 7(1). 61–71. 9 indexed citations

11.

Rosenberg, Jonathan E., Elisabeth I. Heath, Raymond P. Perez, et al.. (2016). Interim analysis of a phase I dose escalation trial of ASG-22CE (ASG-22ME; enfortumab vedotin), an antibody drug conjugate (ADC), in patients (Pts) with metastatic urothelial cancer (mUC). Annals of Oncology. 27. vi273–vi273. 9 indexed citations

12.

Parimi, Sunil, Misha Eliasziw, Scott North, et al.. (2016). Sunitinib maintenance therapy after response to docetaxel in metastatic castration resistant prostate cancer (mCRPC). Investigational New Drugs. 34(6). 771–776. 3 indexed citations

13.

Dalton, Bruce, et al.. (2013). Extensive Necrotizing Fasciitis Associated With Sunitinib Therapy. Clinical Genitourinary Cancer. 12(2). e47–e49. 3 indexed citations

14.

Seah, Jo-An, Srikala S. Sridhar, Lori Wood, et al.. (2013). Neoadjuvant chemotherapy (NC) should be administered to fit patients with newly diagnosed, potentially resectable muscle-invasive urothelial cancer (MIUC) of the bladder – A 2013 CAGMO Consensus Statement and Call for a Streamlined Referral Process. Canadian Urological Association Journal. 7(9-10). 312–312. 16 indexed citations

15.

Vickers, Michael M., Janice L. Pasieka, Elijah Dixon, et al.. (2012). Report from the 13th Annual Western Canadian Gastrointestinal Cancer Consensus Conference; Calgary, Alberta; September 8–10, 2011. Current Oncology. 19(6). 468–477. 1 indexed citations

16.

Larochelle, Pierre, Christian Kollmannsberger, Ross D. Feldman, et al.. (2012). Hypertension Management in Patients with Renal Cell Cancer Treated with Anti-Angiogenic Agents. Current Oncology. 19(4). 202–208. 26 indexed citations

17.

Saad, Fred, Dean Ruether, Scott Ernst, et al.. (2008). The Canadian Uro‐Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone‐refractory prostate cancer progressing after mitoxantrone/prednisone. British Journal of Urology. 102(5). 551–555. 9 indexed citations

18.

Saad, Fred, Dean Ruether, Scott Ernst, Scott North, & Eric Winquist. (2005). Canadian Urologic Oncology Group (CUOG) phase II multi-center study using docetaxel/prednisone in the second line setting for metastatic hormone-refractory prostate cancer in patients progressing after first line mitoxantrone/prednisone. Journal of Clinical Oncology. 23(16_suppl). 4612–4612. 11 indexed citations

19.

Bathe, Oliver F., Scot Dowden, Francis Sutherland, et al.. (2004). Phase II study of neoadjuvant 5-FU + leucovorin + CPT-11 in patients with resectable liver metastases from colorectal adenocarcinoma. BMC Cancer. 4(1). 32–32. 27 indexed citations

20.

Luider, Joanne, Christopher Brown, Diana Quinlan, et al.. (1997). Factors Influencing Yields of Progenitor Cells for Allogeneic Transplantation: Optimization of G-CSF Dose, Day of Collection, and Duration of Leukapheresis. Journal of Hematotherapy. 6(6). 575–580. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact